Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 28;40(3):598-601.
doi: 10.1093/ndt/gfae244.

Prospective validation of initial eculizumab dosing in adults with atypical hemolytic uremic syndrome

Mendy Ter Avest  1 , Caroline Duineveld  2 , Romy N Bouwmeester  3 , Laura M Baas  3 , Lambertus P W J van den Heuvel  3   4   5   6 , Saskia M C Langemeijer  7 , Jack F M Wetzels  2 , Nicole C A J van de Kar  3 , Rob Ter Heine  1 ; CUREiHUS study group
Collaborators, Affiliations

Prospective validation of initial eculizumab dosing in adults with atypical hemolytic uremic syndrome

Mendy Ter Avest et al. Nephrol Dial Transplant. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

N.v.d.K., J.W., and B.v.d.H. are members of the European Reference Network for Rare Kidney Diseases (ERKNet)-Project No 739532. J.W. received grants from Alexion, HiBio, Novartis, and consultancy fees from Novartis, HiBio, and Otsuka. N.v.d.K. received consultancy fees from Roche Pharmaceuticals, Alexion, and Novartis and is sub-investigator in the APL2-C3G trial, Apellis. R.t.H. has received research funding from AMGEN. The other authors declare that they have no conflict of interest.

Figures

Figure 1:
Figure 1:
Eculizumab concentrations for the standard initial phase dosing regimen (dots) and the new initial phase dosing regimen (triangles) at day 7, 14, and 28 of treatment. The colored dots represent patients with comorbidities that could influence pharmacokinetics. The blue dots represent patients with severe proteinuria (standard dose [n = 3], new dose [n = 2]), the red dots represent patients with post-partum HUS (standard dose [n = 1], new dose [n = 2]), and the green dots represent a patient with severe infection (new dose [n = 1]).
See this image and copyright information in PMC

References

    1. Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;368:2169–81. 10.1056/NEJMoa1208981 - DOI - PubMed
    1. European Medicines Agency (EMA) Summary of Product Characteristics Eculizumab (Soliris) . https://www.ema.europa.eu/en/documents/product-information/soliris-epar-... (27 July 2024, date last accessed).
    1. Ter Avest M, Bouwmeester RN, Duineveld C et al. Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective. Nephrol Dial Transplant 2023;38:362–71. 10.1093/ndt/gfac056 - DOI - PMC - PubMed
    1. Duineveld C, Wijnsma KL, Volokhina EB et al. Suboptimal dosing of eculizumab therapy in aHUS? [abstract]. J Am Soc Nephrol 2018;29:694. - PubMed
    1. Bouwmeester RN, Duineveld C, Wijnsma KL et al. Early eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study. Kidney Int Rep 2023;8:91–102. 10.1016/j.ekir.2022.10.013 - DOI - PMC - PubMed

LinkOut - more resources